Chemistry:Mitoquinone mesylate
 | |
| Clinical data | |
|---|---|
| Trade names | MitoQ |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C38H47O7PS |
| Molar mass | 678.82 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mitoquinone mesylate (MitoQ) is a synthetic analogue of coenzyme Q10 which has antioxidant effects. It was first developed in New Zealand in the late 1990s.[1] It has significantly improved bioavailability and improved mitochondrial penetration compared to coenzyme Q10,[2][3] and has shown potential in a number of medical indications,[4][5][6][7] being widely sold as a dietary supplement.[8][9]
A 2014 review found insufficient evidence for the use of mitoquinone mesylate in Parkinson's disease and other movement disorders.[10]
A 2025 British study found that diabetes patients who took daily mitoquinone, a widely available antioxidant, as well as their standard treatment had healthier hearts after four months than those not given the supplement. Mitoquinone was able to reverse the early signs of diabetes-related heart failure over the course of the study.[11]
See also
References
- ↑ Taylor K, Smith R, "Mitoquinone derivatives used as mitochondrially targeted antioxidants.", US patent abandoned 20060229278, published 12 October 2006, assigned to Antipodean Pharmaceuticals Inc
- ↑ "Mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives". Acta Pharmaceutica Sinica B 8 (6): 862–880. October 2018. doi:10.1016/j.apsb.2018.05.006. PMID 30505656.
- ↑ "Coenzyme Q10 Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic Diseases". International Journal of Molecular Sciences 21 (21): 7870. October 2020. doi:10.3390/ijms21217870. PMID 33114148.
- ↑ "Targeting Mitochondria in Cardiovascular Diseases". Current Pharmaceutical Design 22 (37): 5698–5717. 2016. doi:10.2174/1381612822666160822150243. PMID 27549376.
- ↑ "Mitochondria-Targeted Antioxidants: Future Perspectives in Kidney Ischemia Reperfusion Injury". Oxidative Medicine and Cellular Longevity 2016. 2016. doi:10.1155/2016/2950503. PMID 27313826.
- ↑ "Small molecules as therapeutic drugs for Alzheimer's disease". Molecular and Cellular Neurosciences 96: 47–62. April 2019. doi:10.1016/j.mcn.2019.03.001. PMID 30877034.
- ↑ "Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone". Antioxidants 9 (10): 943. October 2020. doi:10.3390/antiox9100943. PMID 33019512.
- ↑ "The Effect of MitoQ on Aging-Related Biomarkers: A Systematic Review and Meta-Analysis". Oxidative Medicine and Cellular Longevity 2018. 2018. doi:10.1155/2018/8575263. PMID 30116495.
- ↑ "Targeting reactive oxygen species (ROS) to combat the age-related loss of muscle mass and function". Biogerontology 21 (4): 475–484. August 2020. doi:10.1007/s10522-020-09883-x. PMID 32447556.
- ↑ "Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone". CNS Drugs 28 (1): 63–8. January 2014. doi:10.1007/s40263-013-0124-4. PMID 24242074.
- ↑ https://medicalxpress.com/news/2025-06-counter-supplement-heart-disease-diabetes.html Kaamya Mehta, British Heart Foundation article about mitoquinone could prevent heart disease in type 2 diabetes patients
 |  |
